Literature DB >> 8707749

In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits.

A L Barry1, P C Fuchs, S D Allen, S D Brown, J H Jorgensen, F C Tenover.   

Abstract

The l-isomer of ofloxacin (levofloxacin) was twice as active as ofloxacin and the d-isomer was inactive against 654 Streptococcus pneumoniae isolates. For disc susceptibility tests of pneumococci, 5 micrograms levofloxacin discs can be used with interpretive criteria of < or = 12 mm for resistant (MIC > or = 8.0 mg/L) and > or = 16 mm for susceptible (MIC < or = 2.0 mg/L). For quality control of levofloxacin tests, S. pneumoniae ATCC 49619 should give zones 20-25 mm in diameter and MICs 0.5-2.0 mg/L.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707749     DOI: 10.1093/jac/37.2.365

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.

Authors:  S K Spangler; G Lin; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2.

Authors:  R Kirk; A Ratcliffe; G Noonan; M Uosis-Martin; D Lyth; O Bardell-Cox; J Massam; P Schofield; A Lyons; D Clare; J Maclean; A Smith; V Savage; S Mohmed; C Charrier; A-M Salisbury; E Moyo; N Ooi; N Chalam-Judge; J Cheung; N R Stokes; S Best; M Craighead; R Armer; A Huxley
Journal:  RSC Med Chem       Date:  2020-09-18

3.  Evaluation of the Dade MicroScan MICroSTREP antimicrobial susceptibility testing panel with selected Streptococcus pneumoniae challenge strains and recent clinical isolates.

Authors:  J H Jorgensen; M L McElmeel; S A Crawford
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

Review 4.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

5.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.